The global biosimilars sale is predicted to reach $17 billion to $20 billion per year by 2020.
After witnessing outstanding success in our last year's conference, we are delighted to hostBiosimilars Europe 2017 - A conference that offers a rare opportunity to its participants to understand and learn from top experts in the biosimilars field and to share experiences. The conference will also provide a platform to discuss the current vital issues, regulatory issues, market assessment and commercialization and globalization.
At present the sales just in Europe is $1 billion yearly. With the entry of first biosimilar in the US market, the sales are expected to be even higher. Though biosimilars are less costly versions of the biologics, its development is much more complex, this makes its regulatory approval and acceptance by the public more difficult when compared to the generic drugs. With many leading biologics losing their patent protection by 2020; the market entry and opportunity for biosimilars are very huge. Being just 10 years old and still in its nascent stage, there is vast scope for improvisation in very stage, from biosimilar development to market approval. There are many regulatory concerns such as labeling, naming and interchangeability yet to be settled. The cost of these products and acceptance by physicians and patients is still a big challenge.
Thus, the Biosimilars Europe 2017 conference offers a rare opportunity to its participants to understand and learn from top experts in the biosimilars field and to share experiences. The conference will also provide a platform to discuss the current vital issues, regulatory issues, market assessment and commercialization and globalization.
The conference will bring together industry experts to explore the strategies to gain insight into new biosimilar development strategies, different characterization and analysis methods, clinical advancement and successful case studies.
Current status of Biosimliars market
Bringing Biosimilars and Biotechnology under one roof
Monoclonal antibody Biosimilars
Commercial perspective of Biosimilars
Ethis and Biosimilars
Risk Management Strategies for Biosimilars
Challenges faced when moving towards globalization
Opportunities in emerging markets
IP issues, naming and labeling issues related to biosimilars
Partnership, new investment and business models
Challenges and opportunities for biobetters and monoclonal antibody biosimilars
Clinical trials strategies and new guidelines for biosimilar clinical trials
Benefits and concerns of interchangeable and biosubstitutes and post authorization monitoring
Bringing biosimilars closer to patients and healthcare professionals
New solutions to demonstrate similarity and different characterization methods
Why Attend Biosimilars Europe Congress?
Global Event in Biosimilars
Developing Biosimilar Market in Europe
20+ Expert Speakers from around the world
Attracting Professionals from Global Pharma / Biotech Industry
Bringing together the key decision makers under one roof
Over 10 hours of dedicated Networking and Interactive sessions
A quality, senior level international audience
An unbeatable Senior Level Speaker Line-Up
Who Will You Meet?
VPs, Directors, Heads, Managers, Scientific Advisors, Consultants, Senior scientists and professionals with intermediate to advance knowledge and experience in the following:
Clinical Immunology Development
Partnering and Licensing
Who Should Attend:
Biosimilars Europe Congress 2017 attracts senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies. Delegates includes VPs, Directors, Heads, Managers, Scientific Advisors, Consultants, Senior scientists and professionals with intermediate to advance knowledge and experience in the following:
Patents & Intellectual Property
Commercial Affairs and Development
Biosimilar Process Development
Research & Development
List of Attendees:
"Bringing together Developers, Key Decision Makers and Solution Providers from the Global Biosimilars Market under One Roof for an ultimate knowledge sharing and networking experience"